Organization | Caris Life Science

Caris Life Science Report issue

For profit Phase 2 Phase 4

Founded: Phoenix AZ United States (1987)

Organization Overview

First Clinical Trial

2019

NCT03834220

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Caris Life Sciences

Active Ingredients

Drugs in Phase 4 Trials (6)

Key: Caris Life Science (0) Acquired (6)

cyclophosphamide (cytoxan) (2 trials)

goserelin (zoladex) (1 trial)

leuprolide (lupron) (1 trial)

pentostatin (nipent) (3 trials)

rituximab (rituxan) (4 trials)

triptorelin (Trelstar) (1 trial)

Drugs in Phase 2 Trials (9)

Key: Caris Life Science (1) Acquired (8)

bendamustine (treanda) (1 trial)

bevacizumab (avastin) (1 trial)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (1 trial)

debio-1347 (1 trial)

denileukin diftitox (ontak) (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

gemcitabine (gemzar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial APIs: 15